

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. QHG of Indiana, Inc.</p> <p>2. 7950 West Jefferson Blvd. Fort Wayne, Indiana 46804-1677</p>	<p>In accordance with letter/application dated May 12, 2015,</p> <p>3. License No. 13-01535-01 is renewed in its entirety to read as follows:</p> <p>4. Expiration Date: August 31, 2025</p> <p>5. Docket No. 030-01594 Reference No.</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p> <p>E. Palladium-103 permitted by 10 CFR 35.400</p> <p>F. Cesium-131 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (North American Scientific, Inc., Model MED 3631; Bard Model STM1251; Best Industries, Model 2301; Implant Sciences Corp., I-Plant, Model 3500; IsoAid, LLC, Model IAI-125A; and Mills Biopharmaceuticals, Inc., Models SL-125 and SH-125)</p> <p>E. Sealed sources (North American Scientific, Inc., Model MED 3633; Best Medical International Inc., Model 2335; and Theragenics Corp. Theraseed, Model 200)</p> <p>F. Sealed sources (IsoRay Medical Inc. Model #CS-1)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1 curie</p> <p>D. 1 curie</p> <p>E. 1 curie</p> <p>F. 1 curie</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-01535-01Docket or Reference No.
030-01594**Amendment No. 75**

- | | | |
|--|--|--|
| G. Any byproduct material permitted by 10 CFR 35.500 | G. Sealed sources (North American Scientific, Inc., Models MED 3601 and Du Pont Merck Pharmaceutical Company NES-8412) | G. 300 millicuries per source and 1200 millicuries total |
| H. Any byproduct material permitted by 10 CFR 31.11 | H. Prepackaged kits | H. 1 millicurie |
| I. Yttrium-90 permitted by 10 CFR 35.1000 | I. Sealed sources as SIR-Spheres (AEA Technology QSA, Inc.) | I. 2 curies |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. through F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- G. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
- H. In vitro studies.
- I. Medical use permitted by 10 CFR 35.1000 in a Sirtex Medical Limited brachytherapy afterloader delivery system.

CONDITIONS

- 10. A. Licensed material may be used or stored only at the licensee's facilities located at 7950 West Jefferson Boulevard, Fort Wayne, Indiana.

B. Licensed material listed in Subitems 6.A. and 6.B. may be used and stored at 7916 West Jefferson Blvd, Fort Wayne, Indiana.
- 11. The Radiation Safety Officer for this license is Randall J. Phillips, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.

13-01535-01

Docket or Reference No.

030-01594

Amendment No. 75**B. The following individuals are authorized users for medical use as indicated:**Authorized UserMaterial and Use

Brett A. Hagedorn, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

John Rock, M.D.

10 CFR 35.100, 35.200, and 31.11.

Rik Stephens, M.D.

10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.

James C. Wehrenberg, M.D.

10 CFR 35.100, 35.200, 35.500, and 31.11.

David B. Janizek, M.D.

10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.

Christine Anne Tremper, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities equal to or less than 33 millicuries), and 35.500.

Randall J. Phillips, M.D.

10 CFR 35.100, 35.200, 35.300, 35.500, 31.11, 35.1000 (limited to yttrium-90 SIR-spheres delivery system).

John Pasalich, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

Stephen R. Phillip, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

Marc Thomas, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

Michael E. Parker, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

Pamela Lee Strange, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

Joseph R. Decamp, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to oral administration of sodium iodide I-131 in quantities equal to or less than 33 millicuries), and 35.500.

Frederick N. Vandeman, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries), and 35.500.

Andre Byard Stovall, M.D.

10 CFR 35.100, 35.200, 35.300, 35.500 and 35.1000 (limited to yttrium-90 SIR-Spheres delivery system).

Christopher Michael Kowalski, M.D.

10 CFR 35.100, 35.200, and 35.500.

Richard W. Sibley, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.500.

Dakshesh S. Patel, M.D.

10 CFR 35.100, 35.200, and 35.500.

Eric V. Heatwole, M.D.

10 CFR 35.100, 35.200, and 35.500.

Shilpa Kashyap, M.D.

10 CFR 35.100, 35.200, and 35.500.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-01535-01Docket or Reference No.
030-01594**Amendment No. 75**Authorized UserMaterial and Use

Rao V. P. Mantravadi, M.D.

10 CFR 35.300 and 35.400.

Stephen Beyer, M.D

10 CFR 35.300.

Shawn Johnson, M.D

10 CFR 35.100, 35.200, 35.300.

John C. Lacunza, M.D

10 CFR 35.100 and 35.200.

Eugene Shih, M.D.

10 CFR 35.100 and 35.200.

Peter C. Hanley, M.D.

10 CFR 35.100 and 35.200.

Scott E. Mattson, D.O.

10 CFR 35.100 and 35.200.

Revati J. Ghatnekar, M.D.

10 CFR 35.100 and 35.200.

Krishnan Ramani, M.D.

10 CFR 35.200.

Mark A. Meier, M.D.

10 CFR 35.200.

Venkata Rama Prasad Nalamolu, M.D.

10 CFR 35.200.

Sabeena Ramrakhiani, M.D.

10 CFR 35.100 and 35.200.

Thomas S. Chung, M.D.

10 CFR 35.300 and 35.400.

Jeffery J. Freeman, M.D.

10 CFR 100, 200, and 300 (limited to the oral administration of sodium iodide I-131).

Nathan D. Comsia, M.D.

10 CFR 35.400.

Richard B. Collins, D.O.

10 CFR 35.100 and 35.200.

Benjamin A. Tourkow, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

Vivek Sharma, M.D.

10 CFR 35.100 and 35.200.

Mark A. Brinkman, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

Andrew J. Norton, M.D.

10 CFR 35.100 and 35.200.

Mark C. Ranck, M.D.

10 CFR 35.400.

Wesley A. Russell, M.D.

10 CFR 35.400.

Indu Rekha Meesa, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131).

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.

13-01535-01

Docket or Reference No.

030-01594

Amendment No. 75Authorized UserMaterial and Use

Edward K. Yi, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

Joel Heitman, M.D.

10 CFR 35.100 and 35.200.

Sanjiv G. Aggarwal, M.D.

10 CFR 35.100 and 35.200.

James A. Arata, M.D.

10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.

Deepchand Bajai, M.D.

10 CFR 35.300 and 35.400.

Andrew V. Barger, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

Ravi No. Bathina, M.D.

10 CFR 35.100 and 35.200.

Jonathan Berger, M.D.

10 CFR 35.100 and 35.200.

John L. Bormann, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Daniel Branam, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

Ryan Buss, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. The manufacturer's training for SIR-Spheres shall include operation of the delivery system, safety procedures, and clinical use of SIR-Spheres.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-01535-01Docket or Reference No.
030-01594**Amendment No. 75**

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 12, 2015;


B. Letters dated May 12, 2015 and June 18, 2015.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date

JUL 30 2015

By



Toye L. Simmons
Materials Licensing Branch
Region III